When a Letter of Award Becomes a Legal Obligation: Lessons from Duopharma’s RM155.3 Million Government Supply Contract
Duopharma Biotech Bhd recently announced that its wholly owned subsidiary, Duopharma (M) Sdn Bhd, had secured a RM155.28 million contract to supply insulin products to public hospitals and clinics nationwide. The contract, awarded by the Malaysian Government, will run for three years from 3 June 2026 to 2 June 2029. As part of the award, the company is required to furnish an irrevocable performance bond of RM2.59 million within 30 days from acceptance of the Letter of Award (LOA).
The contract also contains strict obligations regarding delivery timelines and quality specifications. Failure to comply may result in order cancellations, penalties, or termination. Grounds for termination include failure to provide the performance bond, delays in supply, non-compliance with tender requirements or product specifications, unauthorised equity transfers, or reasons relating to public interest, security, or national interest.
This development highlights several critical legal and commercial takeaways for Malaysian companies navigating government procurement, supply contracts, healthcare products, and highly regulated industries.
Beyond the Milestone: The True Weight of a Letter of Award
When a company receives an LOA, it is natural to celebrate it as a major business milestone. However, from a legal perspective, an LOA is also the exact point where binding contractual obligations lock into place.
Accepting the award may trigger immediate duties. These typically include:
- Submitting a performance bond within a tight window
- Executing formal, long-form contract documents
- Living up to pre-contractual tender representations
- Ensuring immediate supply readiness and insurance coverage
- Securing remaining regulatory approvals and adhering to strict product specifications
Companies must not treat an LOA as a mere announcement or a placeholder document. Once accepted, it immediately exposes the supplier to severe contractual liability if they fail to perform.
Performance Bonds: A Heavy Financial Commitment, Not a Formality
A performance bond is standard practice in government and large-scale commercial contracts, serving as a financial safety net for the project owner or government if the supplier defaults.
In this instance, Duopharma’s required irrevocable performance bond stands at RM2.59 million. For suppliers, this is far from a minor administrative checkbox; it directly impacts cash flow, tying up banking facilities, increasing contingent liabilities, and altering the company’s risk exposure.
Before tendering, companies should assess whether they can procure the required bond within the stipulated timeframe. Failure to provide the bond may itself become a ground for termination.
From a legal risk perspective, companies should carefully review whether a bond is:
- Conditional or unconditional
- The exact triggers for when it can be called
- Whether prior notice is required
- What legal remedies exist if the bond is wrongfully called by the counterparty
Zero Margin for Error: Navigating the Critical Demands of Public Sector Supply
For healthcare products such as insulin, product quality and delivery timelines are not flexible commercial terms. This is because they directly impact public health, hospital operations, and patient care continuity.
The Duopharma contract requires supply within prescribed timelines and quality specifications. Non-compliance may result in cancellation, penalties, or termination. This reflects a broader principle in Malaysian commercial contracting, where goods are supplied for critical sectors, contractual performance is closely tied to regulatory compliance and public interest.
Companies supplying medical products, pharmaceuticals, specialised equipment, food products, safety items, or infrastructure materials must ensure their contract management teams fully grasp the exact technical specifications buried in the tender documents. It is not sufficient for the sales team to land the deal; the legal, regulatory, finance, procurement, logistics, and operations teams must be completely aligned from day one.
Tender Representations Can Become Binding Obligations
A common misconception in procurement exercises is that tender submissions are merely preliminary or pre-contractual documents. In practice, particularly in government procurement, statements made by a supplier during the tender stage may later form part of the contractual framework.
Representations on delivery timelines, technical capability, product specifications, sourcing arrangements, manpower, regulatory approvals, or operational readiness may be relied upon by the procuring authority when awarding the contract. Once the contract is awarded, those representations may be used as benchmarks to assess whether the supplier has complied with its contractual obligations.
This creates legal and commercial risk. If a supplier overstates its capability or gives commitments that its operations team cannot realistically fulfil, the supplier may later face penalties, cancellation of orders, suspension, termination, or even claims for breach of contract.
Navigating the Government’s Broad Power to Terminate
In ordinary commercial contracts, termination rights are usually linked to specific events such as material breach, insolvency, prolonged non-performance, or failure to make payment. Government contracts, however, often contain wider termination rights because the Government is not merely acting as a commercial counterparty. It is also acting in the public interest.
In the Duopharma contract, it was reported that the Government may terminate the contract in several circumstances, including non-compliance with tender requirements, failure to meet product specifications, unauthorised equity transfers, and reasons relating to public interest, security, or national interest.
This is significant for any company contracting with the Government. Public sector contracts may contain clauses that give the Government broader discretion to terminate, suspend, reduce, or vary contractual arrangements where public interest considerations arise. These clauses may go beyond the usual default-based termination provisions found in private commercial contracts.
Suppliers should therefore review termination provisions carefully before accepting a government contract. Particular attention should be given to the grounds of termination, notice requirements, cure periods, consequences of termination, payment for goods or services already supplied, treatment of outstanding purchase orders, and whether the supplier has any right to remedy an alleged default.
The Corporate Lock-In: Why Shareholding Changes Require Permission
A change in shareholding or ownership is not always a purely internal corporate matter. In many commercial arrangements, contracts may contain restrictions on share transfers, changes in control, changes in beneficial ownership, restructuring, mergers, acquisitions, or assignment of rights.
These clauses are common not only in government contracts, but also in joint venture agreements, shareholders’ agreements, financing documents, supply contracts, and regulated industry contracts.
The reason is straightforward. A contract may have been entered into based on the identity, financial strength, technical capability, reputation, regulatory status, or commercial relationship of a particular party. If that party’s ownership or control changes, the other contracting party may want the right to approve, object, renegotiate, or terminate the arrangement.
For companies, this has important corporate and commercial implications. Share transfers, internal group restructurings, mergers and acquisitions, entry of new investors, changes in beneficial ownership, or changes at the holding company level may trigger consent requirements under existing contracts.
Before undertaking any corporate restructuring or change in shareholding, companies should review their existing contracts to determine whether prior written consent, notification, lender approval, regulator approval, board approval, or counterparty approval is required. This review should cover both direct changes in ownership and indirect changes in control.
Failure to obtain the necessary consent may result in serious consequences, including breach of contract, event of default, suspension of contractual rights, cancellation of orders, withholding of payments, acceleration of financing obligations, loss of licence rights, or termination of valuable contracts.
Don’t bid what you can’t deliver
The Duopharma contract is a reminder that an LOA should not be viewed merely as confirmation that a tender has been won. Once accepted, it may trigger immediate legal and commercial obligations, including performance bond requirements, compliance with tender representations, delivery timelines, product specifications, reporting obligations, and exposure to penalties or termination rights.
Before participating in a major tender, companies should carefully assess whether they can comply with all technical, delivery, quality, regulatory, and reporting requirements. They should also consider whether financing and performance bond arrangements are available, whether the tender terms contain unusual penalties or termination rights, whether any change-of-control or equity transfer restrictions may be triggered, and whether subcontracting is permitted.
This review is particularly important in regulated or public-interest sectors such as healthcare, pharmaceuticals, infrastructure, energy, food supply, logistics, and public services. In these sectors, contractual non-compliance may not only result in financial penalties or termination, but may also affect business reputation, regulatory standing, and future tender opportunities.
A tender submission should therefore not be treated as a purely commercial exercise. Every representation made during the tender stage may later become a benchmark for contractual performance after the LOA is accepted. Companies should ensure that their legal, finance, regulatory, technical, and operations teams are aligned before any bid is submitted.
For more insights into the Malaysian legal system such as this, do make sure to follow us on Facebook and Instagram or visit our official website. You can also read our articles on the popular Malaysian news aggregator app Newswav here.